Supernus Pharmaceuticals, Inc. (SUPN)
| Market Cap | 1.63B |
| Revenue (ttm) | 556.35M |
| Net Income (ttm) | 111.13M |
| Shares Out | 52.93M |
| EPS (ttm) | 2.07 |
| PE Ratio | 15.07 |
| Forward PE | 20.16 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 18 |
| Last Price | $31.13 |
| Previous Close | $30.94 |
| Change ($) | 0.19 |
| Change (%) | 0.61% |
| Day's Open | 30.93 |
| Day's Range | 30.81 - 31.50 |
| Day's Volume | 116,706 |
| 52-Week Range | 17.20 - 32.31 |
Supernus (SUPN) delivered earnings and revenue surprises of -57.69% and -0.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centra...
ROCKVILLE, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centra...
Supernus (SUPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ROCKVILLE, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...
Supernus (SUPN) gets FDA approval for ADHD treatment, Qelbree, in pediatric patients 6 to 17 years of age.
The biopharmaceutical company released a regulatory update.
They've both taken a beating, but their fortunes may soon change.
Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade
With solid revenue growth, these stocks have the potential to more than triple over the next few years.
As bond yields retreated to 1.52% after trading as high as 1.62% yesterday, the indices popped. Meanwhile, Q.ai's Artificial Intelligence Systems have crunched the numbers to bring you today's best top ...
Stocks saw mild gains due to optimism after the $1.9 trillion stimulus bill passed the Senate over the weekend. In the meantime, Q.ai's Artificial Intelligence has crunched the numbers to bring you toda...
Their recent struggles may soon give way to rising market interest and more lucrative returns.
ROCKVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 8.06% over the past year to $0.57, whi...
ROCKVILLE, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...
Supernus Pharmaceuticals saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before. The post Top-Rated Stocks: Supernus Pharmaceuticals Sees Composite Rating Climb To 96 ap...
ROCKVILLE, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...
ROCKVILLE, Md., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...
If you pick securities whose earnings return is more than twice that of the 20-year high-quality market corporate bonds, you could increase your probability to unearth value opportunities, in my opinion...
ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...
It has been eight months since we last looked in on a promising biopharma concern named Supernus Pharmaceuticals. Some significant news has posted since then including some recently disclosed encouragin...
The company announced positive results from a clinical trial.
The shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) are up 17.7% at $26.50 at last check, after its experimental drug for attention deficit hyperactivity disorder (ADHD), SPN-812, met its main goal...
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced Monday that its SPN-812 — a commercial treatment for patients with Attention Deficit Hyperactivity Disorder (ADHD), exhibited positive topline resul...
Supernus Pharmaceuticals Inc. shares jumped more than 20% in after-hours trading Tuesday after the company revealed positive results from a study of its potential drug for attention deficit hyperactivit...
ROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...
Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (“Supernus or the “Company”) (NASDAQ: SUPN). Such investors are...
LOS ANGELES--(BUSINESS WIRE)---- $SUPN #classaction--The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) on behalf ...
BENSALEM, Pa.--(BUSINESS WIRE)---- $SUPN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...
LOS ANGELES--(BUSINESS WIRE)---- $SUPN #CLASSACTION--Glancy Prongay & Murray LLP, Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc (SUPN) on Behalf of Investors
ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus or the "Company") (NASDAQ: SUPN). Such investors are adv...
ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call Transcript
Supernus (SUPN) delivered earnings and revenue surprises of 174.07% and 18.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...
ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central ...
Investors who are looking for high return investments might be interested in the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt's method) are in the ...
Greg Patrick to Retire as Chief Financial Officer Greg Patrick to Retire as Chief Financial Officer
Supernus is solidly on track for a new record of net sales this year and is still generating huge amounts of free cash flow.
These stocks are just temporarily inconvenienced large caps in the making.
ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centr...
ROCKVILLE, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centr...
ROCKVILLE, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centr...
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2020 Results - Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2020 Results - Earnings Call Transcript
About SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The co... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date May 1, 2012 |
| CEO Jack Khattar | Employees 563 |
| Stock Exchange NASDAQ | Ticker Symbol SUPN |
Financial Performance
In 2020, SUPN's revenue was $520.40 million, an increase of 32.50% compared to the previous year's $392.76 million. Earnings were $126.95 million, an increase of 12.29%.
Analyst Forecasts
According to 4 analysts, the average rating for SUPN stock is "Buy." The 12-month stock price forecast is 35.00, which is an increase of 12.43% from the latest price.